BioSpace News Archive

An interim analysis of the Phase III P302 study showed Moderna’s investigational flu shot, mRNA-1010, fell short of the statistical threshold for early success.

A California judge denied Elizabeth Holmes’ motion for release pending appeal, ruling that the former Theranos CEO must serve her prison sentence while she appeals her guilty verdict.

Junshi Biosciences announced Tuesday that its ovarian cancer candidate, senaparib, met the primary endpoint in a Phase III interim analysis.

A look at the differences among types of retirement accounts, and how to evaluate which is best for you

Following mixed Phase I/II data for its homocystinuria hopeful pegtarviliase, Aeglea lays off all but 10 employees and launches a sweeping strategic review.

Poolbeg Pharma Plc, a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, confirms that the Company’s Annual Report and Accounts for the period ended 31 December 2022 and the notice of Annual General Meeting 2022 have been posted to shareholders.

Ouster, Inc., a leading provider of high-performance lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries, announced that it has filed a patent infringement complaint with the U.S. International Trade Commission against Hesai Group based in Shanghai, China, and related entities, requesting that the Commission institute an investigation under section 337 of the Tariff Act of 1930.

Evolution Research Group, LLC announced the addition of Alexander N. Prezioso, MD and Alfredo R. Fernandez, MD to the existing medical team at Clinical Pharmacology of Miami, a leading 120-bed phase 1 unit in Miami, FL. CPMI specializes in the execution of complex early phase and NDA-enabling clinical trials in both healthy volunteers and special populations such as those suffering with renal insufficiency, hepatic impairment, diabetes, obesity, and many others.

Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, announced the launch of NEW CentoGenome®, an enhanced Next Generation Sequencing -based assay.

Function Oncology, a precision medicine company advancing a CRISPR-powered personalized functional genomics platform to transform the future of targeted cancer treatment, announced its launch with $28 Million in Series A financing.